Savara Inc.'s stock (NASDAQ:SVRA) plummeted 75.2% Thursday as top-line data from Impala, the phase III trial of Molgradex, showed the study failed to meet its primary endpoint in rare lung disease autoimmune pulmonary alveolar proteinosis.